In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Soverini, Simona;De Benedittis, Caterina;Castagnetti, Fausto;Gugliotta, Gabriele;Mancini, Manuela;Bavaro, Luana;Machova Polakova, Katerina;Linhartova, Jana;Iurlo, Alessandra;RUSSO, Domenico;Pane, Fabrizio;Saglio, Giuseppe;Rosti, Gianantonio;Cavo, Michele;Baccarani, Michele;Martinelli, Giovanni

2016-01-01